Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI) of 30 or higher or a BMI of 27 or higher with at least one obesity-related complication. Participants were randomly assigned to receive the combination of semaglutide 2.4 mg and cagrilintide 2.4 mg (CagriSema) or placebo. The estimated mean change in body weight from baseline to week 68 was -20.4% with CagriSema compared to -3.0% with placebo. Gastrointestinal adverse events occurred in 79.6% in the CagriSema group vs 39.9% in the placebo group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cagrilintide 2•4 mg/week; semaglutide 2•4 mg/week for 68 weeks 17•3% (16•6-18•1) vs placebo; 5•5% (4•3-6•7) vs semaglutide alone 0•4% (not more than the effect of semaglutide alone) Improved physical function (based on IWQOL-Lite-CT and SF-36v2 scores); drug discontinuation due to adverse events 5•9%; weight plateau not reached Garvey et al (2025) 135”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [135]
In the citing paper
“In adults with overweight or obesity, cagrilintide-semaglutide reduced bodyweight by 17•3% (16•6-18•1; placebo-subtracted), 135 along with reductions in waist circumference, blood pressure, and improved physical functioning scores.135”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [135]
In the citing paper
“Gastrointestinal adverse events were slightly more frequent with CagriSema than with semaglutide alone.135”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [135]
In the citing paper
“The effects of the drug combination were greater than the effects of either medication alone, but less than the sum of effects for both medications.135”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [135]
In the citing paper
“In the REDEFINE 1 trial, coadministration of cagrilintide 2.4 mg (a long-acting amylin analog) and semaglutide 2.4 mg (CagriSema) resulted in a 20.4% mean Weight loss at 68 weeks in adults with overweight or obesity.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [78]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citation2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s002 · Cited by 1,393
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Self-citationWeight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Cited by
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., & Pedersen, S. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502082 · Cited by 143
Self-citationNauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Self-citationBrain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 83
“…(an oral small-molecule GLP-1RA), survodutide (a GCGR–GLP-1R co-agonist), retatrutide (a GIPR–GCGR– GLP-1R triple agonist), maridebart cafraglutide (Maritide; a GIPR antagonist–GLP-1R agonist) and cagrilintide–semaglutide (Cagri-Sema; a co-formulated amylin and GLP-1R agonist) 4,90–98 (Table 2).”
New Molecules and Indications for GLP-1 Medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2025) · JAMA · doi:10.1001/jama.2025.14392 · Cited by 50
Billings, L. K., Hsia, S. H., Bays, H. E., Tidemann‐Miller, B., O’Hagan, J., Tham, L. S., Butler, A., KAZDA, C. M., Mather, K. J., & Coşkun, T. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02155-5 · Cited by 47
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Self-citationGLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196758 · Cited by 46
“The Phase 2 clinical trial of CagriSema which combined cagrilintide and semaglutide led to 15.6% weight reduction in T2DM patients while achieving superior glycemic control and better outcomes than each drug alone [53,54].”
InfluentialTuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
Langer, H. T., Gilmore, N. K., Hayden, C. M. T., Roux, J., Bariohay, B., Rouquet, T., Awada, M., Marcotorchino, J., Bournot, L., Nunn, E., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102665 · Cited by 21
“48 Despite larger weight loss than with semaglutide alone, LBM did only contribute 33% to the total weight loss.”
GLP-1 physiology and pharmacology along the gut-brain axis
Beutler, L. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194744 · Cited by 35
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Briere, D. A., Qu, H., Lansu, K., He, M. M., Moyers, J. S., Coşkun, T., Long, A., Allen, D., O’Farrell, L. S., Bowen, B., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102271 · Cited by 26
“Analyses of absolute and percent change in body weight from baseline to days 8, 15, 22, and 29 are shown in Table S12.”
InfluentialScragg, J., Koutoukidis, D. A., Dirksen, C., Heitmann, B. L., & Jebb, S. A. (2025) · Med · doi:10.1016/j.medj.2025.100805 · Cited by 16
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“The results from REDEFINE-1 and REDEFINE-2, demonstrated the efficacy of cagrisema, both in obese people with T2DM and those without T2DM [144,145].”
Buse, J. B., BAJAJ, H. S., Dalskov, S., Donaldson, L., Duus, H. H. H., Fabricius, T. W., Haluzík, M., Lingvay, I., Pedersen, S. D., Pratley, R. E., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00125-7 · Cited by 22
The story of amylin: from physiology to therapy
Secher, A., Lutz, T. A., & Raun, K. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01465-4 · Cited by 16
“Furthermore, additional improvements in lipid levels, blood pressure, C-reactive protein levels and leptin sensitivity as proposed by the leptin-to-sLepR ratio were observed 118,151 .”
InfluentialCagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1
Verma, S., Bøttcher, M., Brown, P., Dicker, D., Rubino, D., Sbraccia, P., Sharma, A. M., Smedegaard, L., Sørrig, R., & Garvey, W. T. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.26055 · Cited by 15
Self-citationConcepción‐Zavaleta, M. J., Fuentes‐Mendoza, J. M., Yovera, J. G. G., Ruvalcaba-Barbosa, G. Y., Cura-Rodríguez, L. D., González-Rodríguez, J. S., Urteaga, L. A. C., Pérez-Reyes, A. I., Aldave, J. E. Q., & Paz‐Ibarra, J. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i37.111435 · Cited by 18
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“A fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg (CagriSema) induced a mean placebo-corrected weight loss of 17.3% over 68 weeks, with participants completing the trial at the maximum dose achieving 20.4% weight reduction 200 .”
InfluentialObesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
Thermogenesis in Adipose Tissue: Adrenergic and Non-Adrenergic Pathways
Hossain, M. A., Poojari, A., & Rabiee, A. (2026) · Cells · doi:10.3390/cells15020131 · Cited by 10
“Cagrisema, a newer candidate, is a combination of a GLP-1 agonist (semaglutide) and an amylin analog (Cagrilintide), which in clinical trials has shown an average weight loss of around 20–22% https://doi.org/10.3390/cells15020131 of body weight in participants over a span of 68 weeks [253].”
InfluentialChrysavgis, L., Mourelatou, N. G., Koloutsou, M. E., Rozani, S., & Cholongitas, Ε. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412130 · Cited by 16
“Further developments include the REDEFINE 1 and 2 trials, which evaluated the dual agonist cagrilintide, a long-acting analogue of amylin, with semaglutide (CagriSema) in over 3400 participants [129].”
Madhu, S. V., Kapoor, N., Das, S., Raizada, N., & Kalra, S. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_680_25 · Cited by 18
Statistics in Medicine — What’s in an Estimand?
Troxel, A. B., Gatsonis, C. A., Hogan, J. W., Hubbard, R. A., Hunter, D. J., & Normand, S. T. (2025) · New England Journal of Medicine · doi:10.1056/nejmp2513633 · Cited by 10
Abu-Nejim, H., & Becker, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01350-7 · Cited by 16
“Additionally, glycemic control is markedly improved, with a higher proportion of patients achieving normoglycemia or HbA1c ≤ 6.5% [167, 168].”
InfluentialDo no harm: managing nausea and vomiting in GLP-1 based obesity therapies
Alhazmi, A., & le Roux, C. W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1788698 · Cited by 10
Revolution in Stroke Treatment Over 50 Years and Predicting Stroke Care in 2050
Broderick, J. P. (2025) · Stroke · doi:10.1161/strokeaha.125.052583 · Cited by 7
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Muskiet, M. H. A., Nardone, M., Rensen, P. C. N., Cherney, D. Z. I., & Cooper, M. E. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01776-3 · Cited by 11
LEAP2 as a therapeutic target in obesity and cardiometabolic disorders
Holm, S. K., Johansen, V. B. I., & Clemmensen, C. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-10007-4 · Cited by 11
Yamauchi, T., Becker, N., Hagemann, C. A., Huang, K.-C., Kiyosue, A., Lim, S., Onishi, Y., Kosuvaripalli, A., Takano, T., & Ishigaki, Y. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00402-4 · Cited by 12
Bhattachar, S., Tham, L. S., Tidemann‐Miller, B., Ibriga, H., Qu, H., Briere, D. A., Haupt, A., Mather, K. J., & Pratt, E. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70439 · Cited by 10
“15,16 The performance of eloralintide in combination with incretins is currently under evaluation (NCT06916065).”
Patil, S., Jha, N., & Jha, M. K. (2026) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2026.100671 · Cited by 24
Gezginer, I., Mazzini, G., Foll, C. L., Kindler, D., Lutz, T. A., & Razansky, D. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102313 · Cited by 7
“These insights are especially relevant as combinatorial pharmacological strategies such as dual amylin/GLP-1 receptor agonists are now showing superior outcomes for weight loss and glycemic control relative to mono-therapy [21,22].”
Nong, K., Shi, Q., Xie, X., Wang, Y., Agarwal, A., Guyatt, G. H., Zhang, H., Gao, Y., Khunti, K., le Roux, C. W., et al. (2026) · BMJ · doi:10.1136/bmj-2026-372161 · Cited by 21
Fat, muscle, and anti-obesity medications in cardiovascular disease prevention
Khan, M. S., Dawood, M. H., Handelsman, Y., Anker, S. D., Coats, A. J. S., Green, J. B., & Butler, J. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag201 · Cited by 9
Li, X., He, C., & Lee, K. (2025) · Kidney International · doi:10.1016/j.kint.2025.09.023 · Cited by 5
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2026) · Peptides · doi:10.1016/j.peptides.2026.171480 · Cited by 7
Obesity and emerging intervention strategies: Mechanistic insights and novel drug targets
Feng, X., Li, S., Li, J., & Su, Z. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003919 · Cited by 7
“[167] Maridebart cafraglutide (AMG133) (Amgen Inc., Thou-sand Oaks, United States) is a long-acting, bispecific GLP-1R/Glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist engineered by conjugating a fully human monoclonal antibody targeting GIPR with two GLP-1 analogue agonist…”
Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists
Khan, M. S., Bhutani, U., Venugopal, H., Saini, A. K., Naidu, V. R., & Kollipara, S. (2026) · Journal of Peptide Science · doi:10.1002/psc.70083 · Cited by 7
“…significant weight loss at 32 weeks with a favorable safety profile, and the combination of cagrilintide and semaglutide (CagriSema, NCT05567796; REDEFINE-1) [71] demonstrated superior weight reduction at 68 weeks, high-lighting synergistic effects on appetite regulation and energy expenditure.”
Park, C., Kim, Y., Raygani, S., & Grunvald, E. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630199 · Cited by 7
Ahmed, M., Hassan, M., Tahir, M., Hussain, M., Islam, F., Khan, G. T., Ahsan, M. N., Shafiq, S. S., Ibrahim, A., Uddin, A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70667 · Cited by 9
Ludwig, M. Q., Coester, B., Gordian, D., Hassan, S., Tomlinson, A. J., Toure, M. H., Christensen, O. P., Lommi, G., Moltke-Prehn, A., Brown, J. M., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01539-3 · Cited by 21
“Treatment with the long-acting amylin analogue cagrilintide 2 induces 11.8% weight loss in humans over 68 weeks and co-administering cagrilintide with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide produces 22.7% weight loss over 68 weeks (versus 16.1% for semaglutide alone) 3–6 .”
InfluentialWeight management treatment in obesity
Rubio, M. Á., & Carreiro, S. M. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107152 · Cited by 7
Aroda, V. R., Buzzetti, R., Dalskov, S., Jain, A. B., Larsen, J. S., Mathieu, C., Pratley, R. E., Videmark, A. N., Watt, T., & Buse, J. B. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00126-9 · Cited by 10
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 15
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
“In the phase III REDEFINE 1 trial [122], weekly CagriSema (combination of amylin-based cagrilintide and incretin-based semaglutide) (2.4 mg each) produced a mean weight loss of 20.4% versus 3.0% with placebo at 68 weeks (difference − 17.3 percentage points; p < 0.001).”
InfluentialSelf-citationMerhi, Z. O. (2026) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeag015 · Cited by 6
Weight maintenance after discontinuation of GLP-1 therapies
Moiz, A., Filion, K. B., Knäuper, B., Tsoukas, M. A., Brazeau, A.-S., Zolotarova, T., Lelièvre, A., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103992 · Cited by 7
“6 Amylin analogues like cagrilintide are also under investigation as adjuncts to enhance satiety and reduce energy intake, 98 but their role after GLP-1 RA discontinuation has not been defined.”
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
“CagriSema consistently achieves weight reductions of approximately 20 – 22%, comparable to tirzepatide but through a mechanistically distinct pathway, which may offer advantages in tolerability or sequencing [90,51].”
InfluentialCVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum
Schnell, O., Agarwal, A., Azizi, M., Ballwieser, D. A., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Bugianesi, E., Cebrián, A., Ceriello, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03140-0 · Cited by 6
Self-citationOlsen, M. B., GRIFFIN, J., Hövelmann, U., Macura, S., Hagen, B. F., Hesse, D., & Heise, T. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70753 · Cited by 4
Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps
Dubin, R. L., Sanders, T. N., Schwab, H. M., Heymsfield, S. B., & Greenway, F. L. (2026) · Obesity · doi:10.1002/oby.70212 · Cited by 3
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 12
“In the phase III REDEFINE 1 trial, [122] weekly CagriSema (combination of amylin-based cagrilintide and incretin-based semaglutide) (2.4 mg each) produced a mean weight loss of 20.4 % vs 3.0 % with placebo at 68 weeks (difference -17.3 percentage points; p < 0.001).”
InfluentialSelf-citationZheng, N., Chen, R., Yang, L., Xu, P., Wang, X., Sun, X., Lin, Y.-X., Qiu, J., Su, X., Wang, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02893 · Cited by 4
Advances in incretin-based drug discovery in 2025
Müller, T. D. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01219-4 · Cited by 4
“Systolic and diastolic blood pressure decreased similarly in both groups, without notable effects on cholesterol or plasma levels of lipids 2 .”
InfluentialMitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro
Old, V. J., Davies, M. J., Denniff, M. J., Choudhary, P., Eastley, N. C., Ashford, R. U., & Watson, E. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70254 · Cited by 6
Self-citationLarsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Crispino, S. P., Nusca, A., Ferro, A., Cricco, R., Ciancio, M., Segreti, A., Cavallari, I., Sabatino, M., Potena, L., Ussia, G. P., et al. (2025) · Biomolecules · doi:10.3390/biom15111574 · Cited by 6
“The ongoing REDEFINE 3 trial will further assess its impact on MACE in patients with established cardiovascular disease [99,100].”
Leptin and G-protein coupled receptor (GPCR) signaling: Therapeutic potential in obesity
Sun, X., Brueck, L., Yang, D., Sheets, P. L., Zhou, B., & Ren, H. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110768 · Cited by 5
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?
Kylies, D., Dreher, L., & Wenzel, U. O. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01374-7 · Cited by 2
Friedman, A. N., Oultache, I., & Hovey, R. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.03.037 · Cited by 3
Khachaturov, M., & Goulis, D. G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70822 · Cited by 3
Rega, M., Petraglia, F. M., D’Ursi, L., Buonocore, M., Criscuolo, D., & Santoro, A. (2026) · Clinical bioenergetics · doi:10.3390/clinbioenerg2010005 · Cited by 2
“Combining cagrilintide and semaglutide has produced meaningful weight loss in adults with overweight or obesity, supporting the use of multi-pathway peptide treatments in practice [250].”
The year in cardiovascular medicine 2025: the top 10 papers in diabetes and metabolic disorders
Cosentino, F., Marx, N., & Cannon, C. P. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehaf1125 · Cited by 2
Wang, Y., Feng, Z., & Yu, L. (2025) · The Innovation Medicine · doi:10.59717/j.xinn-med.2025.100150 · Cited by 2
The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities
Henney, A. E., & Wilding, J. P. H. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.84 · Cited by 4
Self-citationRenke, G., & Chinellato, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093890 · Cited by 3
“Cagrilintide + Semaglu-tide: a phase III study evaluating this combination reported 20,4% weight loss at 68 weeks—higher than semaglutide alone—with greater satiety and less rebound effect after termination [37].”
Should weight loss be the first-line treatment for obstructive sleep apnoea? A pro–con debate
Patel, S. R., & Ryan, S. (2026) · European Respiratory Review · doi:10.1183/16000617.0255-2025 · Cited by 3
“These include drugs combining additional effects, including triple hormone (GLP-1, GIP and glucagon) receptor agonists such as retatrutide [67], and combined GLP-1 and amylin receptor agonists such as amycretin [68] or semaglutide/cagrilintide [69].”
GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies
Wang, X., Lin, R., Sun, Q., Xin, X., & Feng, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108331 · Cited by 2
Bariatric Surgery in the Era of GLP1RA: A Narrative Review
Muhundan, M., & Dash, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03494-7 · Cited by 2
GLP ‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review
Woo, S., Zhu, G., Castro, C., Phuong, A., Roy, A., Davis, C. N., & Kranzler, H. R. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70312 · Cited by 3
Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1
Bruna-Mejías, A., Valenzuela‐Fuenzalida, J. J., Oyanedel-Amaro, G., Figueroa-Puig, J., Cabezas-Salgado, J. J., Orellana-Donoso, M., Cifuentes-Suazo, G., & Loro-Ferrer, J. F. (2026) · Nutrients · doi:10.3390/nu18111781 · Cited by 3
Curto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
Alhazmi, A., & le Roux, C. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71074 · Cited by 2
Islam, T., & Uddin, M. N. (2025) · EMJ Diabetes · doi:10.33590/emjdiabet/rkyo7834 · Cited by 1
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Self-citationCiudin, A., Baker, J. L., Belančić, A., Busetto, L., Diker, D., Fábryová, Ľ., Frühbeck, G., Goossens, G. H., Gordon, J., Monami, M., et al. (2026) · medRxiv · doi:10.64898/2026.04.19.26351196 · Cited by 1
Self-citationAkwe, J. A., Fongeh, K., Jung, S. A., Hall, M. A. K., Patidar, V., & Shin, Y. M. (2025) · Cureus · doi:10.7759/cureus.91677 · Cited by 5
Hamarsheh, S., Jaber, A. R., Abu-Khazneh, O., Andonie, C. R., Majadleh, S., Zahran, A., & Ayesh, H. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70248 · Cited by 2
Ibsen, D. B., Kobayashi, R., Bruun, J. M., & Drouin‐Chartier, J. (2025) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.07.040 · Cited by 1
Bellido, V., le Roux, C. W., Ekinci, E. I., Bjornstad, P., Frías, J. P., Giblin, K. A., Eyde, S., Park, S. Y., Ferro, J., Johnson, C., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01861-1 · Cited by 8
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 2
What is the role of amylin as an emerging therapeutic agent in obesity?
Bogaerts, G., Lommi, G., & Lutz, T. A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2668391 · Cited by 1
Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care
Hales, C. M. (2025) · New England Journal of Medicine · doi:10.1056/nejme2509700 · Cited by 1
Lisco, G., Tullio, A. D., Disoteo, O., Dicorato, P., Tortora, A., Geronimo, V. D., & Triggiani, V. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10033-w · Cited by 1
Zhou, Y., Xu, P., Lu, J., Xu, S., Qiu, W., Ning, X., Xu, J., & Zheng, N. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00558 · Cited by 3
Structurally defining neurokinin selectivity to improve NK2R agonists
Pavlovskyi, A., Ren, Y., Gestal-Mato, M., Olsen, O. H., Schwartz, T. W., Gerhart‐Hines, Z., & Liu, X. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-026-01820-9 · Cited by 1
“EB1002 contains substitutions in positions 2 (S2K) and 3 (F3Y), which correspond to positions 5 and 6 in NKA.”
Bousch, C., Bérubé, F., Babych, M., Ongeri, S., & Bourgault, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062598 · Cited by 2
Abdallah, H., Khalil, M., Mahdi, L., Pietragalla, G., Faienza, M. F., Garruti, G., & Portincasa, P. (2026) · Nutrients · doi:10.3390/nu18142317 · Cited by 1
Cagrilintide–Semaglutide in Adults with Overweight or Obesity
Chi, H., Yang, H., & Deng, Y. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2513141 · Cited by 1
Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050
Mishra, N. K. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.103260 · Cited by 2
Luca, M. D., Modestino, M. R., Alsergani, A. H., Gabriele, M., Galzerano, D., Mallardo, M., Saldamarco, L., Bossone, E., & Cittadini, A. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103328 · Cited by 4
GIPR:GCGR co-agonism restores normal weight in obese rodents
Pérez–Tilve, D., Zhang, F., Zhang, Y., Lohman, K., Sorrell, J. E., Vick, A., Müller, T. D., Tschoep, M. H., & DiMarchi, R. D. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102365 · Cited by 1
“Similar occurrences are reported for use of CagriSema [26].”
Al-Harbi, F. A., Alsaif, A. K., Almutairi, A. M., Alshehri, H. J., Aleidan, E. A., Alabdulaaly, G. S., Alanazi, M. E., & Azzam, A. Y. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100414 · Cited by 1
A new era in reducing obesity and the risk of cardiovascular disease events in preeclampsia
Malik, A., & Malik, R. A. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004250 · Cited by 1
Metadata
- Authors
- Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., & Wilding, J. P. H.
- Affiliations
- University of Alabama at Birmingham (US)
- Helmholtz Munich (DE)
- Novo Nordisk, Søborg, Denmark
- University of Leicester (GB)
- University of Helsinki (FI)
- Washington Center for Weight Management and Research (US)
- University of Rome Tor Vergata (IT)
- University of Pennsylvania (US)
- Novo Nordisk (Denmark) (DK)
- University of Liverpool (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-08-14
- Volume
- 393
- Issue
- 7
- Pages
- 635-647
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4411522078
- Semantic Scholar
- 88a7f366045169f809d813a8da85f107c6d472ed
- Cited by
- 238
- References
- 32
- Citations by year
- 2026: 181 · 2025: 57
- FWCI
- 133.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- cagrilintide, semaglutide, combination therapy, obesity, overweight, weight loss, GLP-1 receptor agonists, GIP receptor agonist, obesity-related comorbidities, lifestyle intervention, treatment policy estimand, cardiovascular outcomes, GIP/GLP-1 receptor agonist
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Double-Blind Method, Drug Combinations, Female, Humans, Hypertension, Male, Middle Aged, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Anti-Obesity Agents, Dyslipidemias, Overweight, Glucagon-Like Peptide 1, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.